WO2005037315A1 - 中皮腫治療剤 - Google Patents
中皮腫治療剤 Download PDFInfo
- Publication number
- WO2005037315A1 WO2005037315A1 PCT/JP2004/015674 JP2004015674W WO2005037315A1 WO 2005037315 A1 WO2005037315 A1 WO 2005037315A1 JP 2004015674 W JP2004015674 W JP 2004015674W WO 2005037315 A1 WO2005037315 A1 WO 2005037315A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- receptor
- mesothelioma
- cells
- human
- Prior art date
Links
- 206010027406 Mesothelioma Diseases 0.000 title claims abstract description 58
- 239000003814 drug Substances 0.000 title claims abstract description 30
- 229940124597 therapeutic agent Drugs 0.000 title claims abstract description 20
- 102000010781 Interleukin-6 Receptors Human genes 0.000 claims abstract description 182
- 108090001005 Interleukin-6 Proteins 0.000 claims abstract description 179
- 102000004889 Interleukin-6 Human genes 0.000 claims abstract description 178
- 229940100601 interleukin-6 Drugs 0.000 claims abstract description 175
- 108010038501 Interleukin-6 Receptors Proteins 0.000 claims abstract description 167
- 239000005557 antagonist Substances 0.000 claims abstract description 30
- 102000005962 receptors Human genes 0.000 claims description 53
- 108020003175 receptors Proteins 0.000 claims description 53
- 208000006178 malignant mesothelioma Diseases 0.000 claims description 33
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims description 19
- 102000052611 human IL6 Human genes 0.000 claims description 19
- 101001076414 Mus musculus Interleukin-6 Proteins 0.000 claims description 17
- 206010035603 Pleural mesothelioma Diseases 0.000 claims description 17
- 239000003966 growth inhibitor Substances 0.000 claims description 16
- 201000005282 malignant pleural mesothelioma Diseases 0.000 claims description 13
- 239000004480 active ingredient Substances 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 230000003042 antagnostic effect Effects 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 178
- 238000000034 method Methods 0.000 description 102
- 108090000623 proteins and genes Proteins 0.000 description 46
- 210000004408 hybridoma Anatomy 0.000 description 39
- 108091007433 antigens Proteins 0.000 description 28
- 102000036639 antigens Human genes 0.000 description 28
- 108090000765 processed proteins & peptides Proteins 0.000 description 28
- 239000000427 antigen Substances 0.000 description 27
- 230000000638 stimulation Effects 0.000 description 27
- 108020004414 DNA Proteins 0.000 description 23
- 238000004519 manufacturing process Methods 0.000 description 23
- 230000027455 binding Effects 0.000 description 21
- 239000013604 expression vector Substances 0.000 description 21
- 241000124008 Mammalia Species 0.000 description 18
- 230000006711 vascular endothelial growth factor production Effects 0.000 description 18
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 17
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 17
- 230000001235 sensitizing effect Effects 0.000 description 17
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 16
- 102000004495 STAT3 Transcription Factor Human genes 0.000 description 16
- 239000012228 culture supernatant Substances 0.000 description 16
- 230000036961 partial effect Effects 0.000 description 16
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 13
- 206010035226 Plasma cell myeloma Diseases 0.000 description 13
- 239000012894 fetal calf serum Substances 0.000 description 13
- 201000000050 myeloid neoplasm Diseases 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 12
- 230000012010 growth Effects 0.000 description 12
- 230000006698 induction Effects 0.000 description 12
- 108020004999 messenger RNA Proteins 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 125000003275 alpha amino acid group Chemical group 0.000 description 11
- 239000002299 complementary DNA Substances 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 11
- 210000002865 immune cell Anatomy 0.000 description 11
- 230000001939 inductive effect Effects 0.000 description 11
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- 230000004071 biological effect Effects 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 10
- 230000035755 proliferation Effects 0.000 description 10
- 208000023504 respiratory system disease Diseases 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 9
- 230000007910 cell fusion Effects 0.000 description 9
- 230000001419 dependent effect Effects 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 230000003053 immunization Effects 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 230000026731 phosphorylation Effects 0.000 description 9
- 238000006366 phosphorylation reaction Methods 0.000 description 9
- 241000283707 Capra Species 0.000 description 8
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 7
- 238000012258 culturing Methods 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 108010011903 peptide receptors Proteins 0.000 description 7
- 102000014187 peptide receptors Human genes 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 6
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 230000010261 cell growth Effects 0.000 description 6
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 6
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 6
- 239000003623 enhancer Substances 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 229940104230 thymidine Drugs 0.000 description 6
- 208000002151 Pleural effusion Diseases 0.000 description 5
- 229920002684 Sepharose Polymers 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 230000005540 biological transmission Effects 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000010353 genetic engineering Methods 0.000 description 5
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 5
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 125000005647 linker group Chemical group 0.000 description 5
- 238000010647 peptide synthesis reaction Methods 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 210000004224 pleura Anatomy 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 4
- 241000255789 Bombyx mori Species 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
- 108060001084 Luciferase Proteins 0.000 description 4
- 241000208125 Nicotiana Species 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 239000012979 RPMI medium Substances 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- -1 polyethylene Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 230000029058 respiratory gaseous exchange Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 238000003163 cell fusion method Methods 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 239000012847 fine chemical Substances 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 230000009422 growth inhibiting effect Effects 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 2
- 241001385733 Aesculus indica Species 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 101150074155 DHFR gene Proteins 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 108010025815 Kanamycin Kinase Proteins 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- 244000061176 Nicotiana tabacum Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 241000609499 Palicourea Species 0.000 description 2
- 241000276498 Pollachius virens Species 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 102000006646 aminoglycoside phosphotransferase Human genes 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 210000000628 antibody-producing cell Anatomy 0.000 description 2
- 239000010425 asbestos Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 101150066555 lacZ gene Proteins 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000000527 lymphocytic effect Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229960004452 methionine Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 210000003516 pericardium Anatomy 0.000 description 2
- 210000001322 periplasm Anatomy 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 229910052895 riebeckite Inorganic materials 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000012090 serum-supplement Substances 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 108010054404 Adenylyl-sulfate kinase Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 101100020619 Arabidopsis thaliana LATE gene Proteins 0.000 description 1
- 101100480620 Arabidopsis thaliana TAT3 gene Proteins 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 101100136076 Aspergillus oryzae (strain ATCC 42149 / RIB 40) pel1 gene Proteins 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001609030 Brosme brosme Species 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 101100459439 Caenorhabditis elegans nac-2 gene Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 102100021579 Enhancer of filamentation 1 Human genes 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010063599 Exposure to chemical pollution Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 244000287680 Garcinia dulcis Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101800000791 Hemagglutinin-esterase-fusion glycoprotein chain 1 Proteins 0.000 description 1
- 101100286713 Homo sapiens IL6 gene Proteins 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 238000000719 MTS assay Methods 0.000 description 1
- 231100000070 MTS assay Toxicity 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 101100286719 Mus musculus Il6 gene Proteins 0.000 description 1
- 101000615617 Mus musculus Mineralocorticoid receptor Proteins 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241001515850 Satellite Nucleic Acids Species 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 102100027662 Sphingosine kinase 2 Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108700027337 Suppressor of Cytokine Signaling 3 Proteins 0.000 description 1
- 102100024283 Suppressor of cytokine signaling 3 Human genes 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 101100068489 Vicia faba AGPC gene Proteins 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- HFNQLYDPNAZRCH-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O.OC(O)=O HFNQLYDPNAZRCH-UHFFFAOYSA-N 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000009850 completed effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 208000013210 hematogenous Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000058223 human VEGFA Human genes 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000001937 intercostal nerve Anatomy 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000005033 mesothelial cell Anatomy 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000013365 molecular weight analysis method Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 101150040383 pel2 gene Proteins 0.000 description 1
- 101150050446 pelB gene Proteins 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 201000002513 peritoneal mesothelioma Diseases 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 229940081969 saccharomyces cerevisiae Drugs 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940126622 therapeutic monoclonal antibody Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Mobile Radio Communication Systems (AREA)
Abstract
Description
Claims
Priority Applications (18)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2542691A CA2542691C (en) | 2003-10-17 | 2004-10-15 | Il-6 antagonist for use as mesothelioma therapeutic agent |
KR1020067007246A KR101193708B1 (ko) | 2003-10-17 | 2004-10-15 | 중피종 치료제 |
ES04792816T ES2392824T3 (es) | 2003-10-17 | 2004-10-15 | Agente terapéutico contra el mesotelioma |
SI200431946T SI1690550T1 (sl) | 2003-10-17 | 2004-10-15 | Terapevtska sredstva za mezoteliom |
AU2004281139A AU2004281139B2 (en) | 2003-10-17 | 2004-10-15 | Therapeutic agent for mesothelioma |
EP04792816A EP1690550B1 (en) | 2003-10-17 | 2004-10-15 | Therapeutic agent for mesothelioma |
CN200480031888XA CN1874790B (zh) | 2003-10-17 | 2004-10-15 | 间皮瘤治疗剂 |
DK04792816.3T DK1690550T3 (da) | 2003-10-17 | 2004-10-15 | Terapeutisk middel til mesothelioma |
PL04792816T PL1690550T3 (pl) | 2003-10-17 | 2004-10-15 | Środek do leczenia międzybłoniaka |
MXPA06003768A MXPA06003768A (es) | 2003-10-17 | 2004-10-15 | Agente terapeutico para el mesotelioma. |
NZ546557A NZ546557A (en) | 2003-10-17 | 2004-10-15 | Therapeutic agent for mesothelioma comprising interleukin-6 |
BRPI0415505-0A BRPI0415505A (pt) | 2003-10-17 | 2004-10-15 | agente terapêutico para mesotelioma |
JP2005514876A JP4651541B2 (ja) | 2003-10-17 | 2004-10-15 | 中皮腫治療剤 |
US10/575,455 US20070134242A1 (en) | 2003-10-17 | 2004-10-15 | Mesothelioma therapeutic agent |
IL174909A IL174909A (en) | 2003-10-17 | 2006-04-10 | Pharmaceutical compositions containing an interleukin-6 antagonist |
NO20061906A NO20061906L (no) | 2003-10-17 | 2006-04-28 | Terapeutisk middel for mesoteliom |
HK07101545.1A HK1096588A1 (en) | 2003-10-17 | 2007-02-09 | Therapeutic agent for mesothelioma |
US12/081,126 US8802092B2 (en) | 2003-10-17 | 2008-04-10 | Mesothelioma therapeutic agent |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003358152 | 2003-10-17 | ||
JP2003-358152 | 2003-10-17 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/575,455 A-371-Of-International US20070134242A1 (en) | 2003-10-17 | 2004-10-15 | Mesothelioma therapeutic agent |
US12/081,126 Continuation US8802092B2 (en) | 2003-10-17 | 2008-04-10 | Mesothelioma therapeutic agent |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005037315A1 true WO2005037315A1 (ja) | 2005-04-28 |
Family
ID=34463281
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/015674 WO2005037315A1 (ja) | 2003-10-17 | 2004-10-15 | 中皮腫治療剤 |
Country Status (23)
Country | Link |
---|---|
US (2) | US20070134242A1 (ja) |
EP (1) | EP1690550B1 (ja) |
JP (1) | JP4651541B2 (ja) |
KR (1) | KR101193708B1 (ja) |
CN (1) | CN1874790B (ja) |
AR (1) | AR046290A1 (ja) |
AU (1) | AU2004281139B2 (ja) |
BR (1) | BRPI0415505A (ja) |
CA (1) | CA2542691C (ja) |
DK (1) | DK1690550T3 (ja) |
ES (1) | ES2392824T3 (ja) |
HK (1) | HK1096588A1 (ja) |
IL (1) | IL174909A (ja) |
MX (1) | MXPA06003768A (ja) |
MY (1) | MY149856A (ja) |
NO (1) | NO20061906L (ja) |
NZ (1) | NZ546557A (ja) |
PL (1) | PL1690550T3 (ja) |
RU (2) | RU2392967C2 (ja) |
SI (1) | SI1690550T1 (ja) |
TW (1) | TWI350175B (ja) |
WO (1) | WO2005037315A1 (ja) |
ZA (1) | ZA200602973B (ja) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011013786A1 (ja) * | 2009-07-31 | 2011-02-03 | Maeda Shin | 癌の転移抑制剤 |
JP5191235B2 (ja) * | 2005-10-21 | 2013-05-08 | 中外製薬株式会社 | 心疾患治療剤 |
US8470316B2 (en) | 2005-10-14 | 2013-06-25 | Chugai Seiyaku Kabushiki Kaisha | Agents for suppressing damage to transplanted islets after islet transplantation |
JP2014509510A (ja) * | 2011-03-03 | 2014-04-21 | アペクシジェン, インコーポレイテッド | 抗il−6受容体抗体およびその使用方法 |
US9260516B2 (en) | 2006-04-07 | 2016-02-16 | Osaka University | Method for promoting muscle regeneration by administering an antibody to the IL-6 receptor |
JP6051049B2 (ja) * | 2010-05-28 | 2016-12-21 | 中外製薬株式会社 | 抗腫瘍t細胞応答増強剤 |
US9725514B2 (en) | 2007-01-23 | 2017-08-08 | Shinshu University | Chronic rejection inhibitor |
US10662245B2 (en) | 2008-09-26 | 2020-05-26 | Chugai Seiyaku Kabushiki Kaisha | Methods of reducing IL-6 activity for disease treatment |
US10697883B2 (en) | 2015-05-19 | 2020-06-30 | National Center Of Neurology And Psychiatry | Method for determining application of therapy to multiple sclerosis (MS) patient |
US10717781B2 (en) | 2008-06-05 | 2020-07-21 | National Cancer Center | Neuroinvasion inhibitor |
US10774148B2 (en) | 2015-02-27 | 2020-09-15 | Chugai Seiyaku Kabushiki Kaisha | Composition for treating IL-6-related diseases |
US10782290B2 (en) | 2013-06-11 | 2020-09-22 | National Center Of Neurology And Psychiatry | Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy |
US11046784B2 (en) | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
US11248053B2 (en) | 2007-09-26 | 2022-02-15 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
US11332533B2 (en) | 2007-09-26 | 2022-05-17 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant region |
US11359194B2 (en) | 2008-04-11 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding two or more antigen molecules repeatedly |
US11692037B2 (en) | 2017-10-20 | 2023-07-04 | Hyogo College Of Medicine | Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion |
US11851486B2 (en) | 2017-05-02 | 2023-12-26 | National Center Of Neurology And Psychiatry | Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils |
US11891434B2 (en) | 2010-11-30 | 2024-02-06 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10324639A (ja) | 1997-03-21 | 1998-12-08 | Chugai Pharmaceut Co Ltd | Il−6アンタゴニストを有効成分として含有する感作t細胞関与疾患の予防・治療剤 |
UA80091C2 (en) | 2001-04-02 | 2007-08-27 | Chugai Pharmaceutical Co Ltd | Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist |
KR101080021B1 (ko) * | 2002-02-14 | 2011-11-04 | 추가이 세이야쿠 가부시키가이샤 | 항체함유 용액제제 |
GB2401040A (en) | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
US8398980B2 (en) * | 2004-03-24 | 2013-03-19 | Chugai Seiyaku Kabushiki Kaisha | Subtypes of humanized antibody against interleuken-6 receptor |
AR057582A1 (es) | 2005-11-15 | 2007-12-05 | Nat Hospital Organization | Agentes para suprimir la induccion de linfocitos t citotoxicos |
AR059213A1 (es) * | 2006-01-27 | 2008-03-19 | Univ Keio | Agentes terapeuticos para enfermedades que involucran neovascularizacion coroidal |
US7906117B2 (en) | 2007-05-21 | 2011-03-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
US9701747B2 (en) | 2007-05-21 | 2017-07-11 | Alderbio Holdings Llc | Method of improving patient survivability and quality of life by anti-IL-6 antibody administration |
US8404235B2 (en) | 2007-05-21 | 2013-03-26 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
US20090238825A1 (en) * | 2007-05-21 | 2009-09-24 | Kovacevich Brian R | Novel rabbit antibody humanization methods and humanized rabbit antibodies |
US8252286B2 (en) | 2007-05-21 | 2012-08-28 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
HUE043782T2 (hu) | 2007-05-21 | 2019-09-30 | Alderbio Holdings Llc | IL-6 elleni antitestek és alkalmazásuk |
EP2162469A4 (en) * | 2007-05-21 | 2012-08-01 | Alderbio Holdings Llc | NEW METHODS OF HUMANIZING RABBIT ANTIBODIES AND HUMANIZED RABBIT ANTIBODIES |
US8178101B2 (en) * | 2007-05-21 | 2012-05-15 | Alderbio Holdings Inc. | Use of anti-IL-6 antibodies having specific binding properties to treat cachexia |
US8062864B2 (en) | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
PE20091174A1 (es) * | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
CN102159709B (zh) * | 2008-07-30 | 2013-07-24 | 国立大学法人冈山大学 | 用于恶性间皮瘤的新型治疗剂和免疫刺激剂 |
US9212223B2 (en) | 2008-11-25 | 2015-12-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
US8420089B2 (en) | 2008-11-25 | 2013-04-16 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
US9452227B2 (en) | 2008-11-25 | 2016-09-27 | Alderbio Holdings Llc | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments |
MX2011005408A (es) * | 2008-11-25 | 2011-06-16 | Alder Biopharmaceuticals Inc | Antagonistas de il-6 para prevenir o tratar la trombosis. |
US8323649B2 (en) | 2008-11-25 | 2012-12-04 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
US8337847B2 (en) | 2008-11-25 | 2012-12-25 | Alderbio Holdings Llc | Methods of treating anemia using anti-IL-6 antibodies |
US8992920B2 (en) | 2008-11-25 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
BR112012009828B8 (pt) | 2009-10-26 | 2022-10-25 | Hoffmann La Roche | Método para a produção de uma imunoglobulina glicosilada e seu uso |
WO2011066374A2 (en) | 2009-11-24 | 2011-06-03 | Alder Biopharmaceuticals, Inc. | Antagonists of il-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
US9775921B2 (en) | 2009-11-24 | 2017-10-03 | Alderbio Holdings Llc | Subcutaneously administrable composition containing anti-IL-6 antibody |
AR080428A1 (es) | 2010-01-20 | 2012-04-11 | Chugai Pharmaceutical Co Ltd | Formulaciones liquidas estabilizadas contentivas de anticuerpos |
WO2012014190A2 (en) * | 2010-07-25 | 2012-02-02 | New York University | Compositions and methods for prognosis of mesothelioma |
MX2013005024A (es) | 2010-11-08 | 2013-11-21 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti-il-6 receptor administrado subcutaneamente. |
ES2847891T3 (es) | 2010-11-23 | 2021-08-04 | Vitaeris Inc | Anticuerpos anti-IL-6 para el tratamiento de la mucositis oral |
WO2012167173A1 (en) | 2011-06-02 | 2012-12-06 | The University Of Louisville Research Foundation, Inc. | Anti-nucleolin agent-conjugated nanoparticles |
MX339762B (es) | 2011-09-28 | 2016-05-27 | Univ Autonoma Del Estado De Morelos | Metalopeptidos inmunomoduladores (immp) y composiciones que los contienen. |
JO3370B1 (ar) | 2011-11-10 | 2019-03-13 | Regeneron Pharma | طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6 |
SG11201504106XA (en) | 2012-12-06 | 2015-07-30 | Univ Kanazawa Nat Univ Corp | Therapeutic method for mesothelioma |
JP6563910B2 (ja) | 2013-07-04 | 2019-08-21 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 血清サンプル中の抗薬物抗体を検出するための干渉抑制イムノアッセイ |
EP3291839A1 (en) | 2015-05-05 | 2018-03-14 | The University of Louisville Research Foundation, Inc. | Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and mri and/or x-ray contrast agents |
WO2017147169A1 (en) | 2016-02-22 | 2017-08-31 | Ohio State Innovation Foundation | Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin a analogues or metabolites, and estradiol metabolites |
US20190060286A1 (en) | 2016-02-29 | 2019-02-28 | University Of Florida Research Foundation, Incorpo | Chemotherapeutic Methods |
US11033496B2 (en) | 2017-03-17 | 2021-06-15 | The Regents Of The University Of Michigan | Nanoparticles for delivery of chemopreventive agents |
EP3947737A2 (en) | 2019-04-02 | 2022-02-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting and preventing cancer in patients having premalignant lesions |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US521628A (en) | 1894-06-19 | Housekeeping-cabinet | ||
JPH02188600A (ja) | 1989-01-17 | 1990-07-24 | Chugai Pharmaceut Co Ltd | Bsf↓2アンタゴニスト |
JPH03219894A (ja) | 1990-01-26 | 1991-09-27 | Chuzo Kishimoto | gp130蛋白質に対する抗体 |
WO1992019759A1 (en) | 1991-04-25 | 1992-11-12 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin 6 receptor |
US5210075A (en) | 1990-02-16 | 1993-05-11 | Tanabe Seiyaku Co., Ltd. | Interleukin 6 antagonist peptides |
FR2694767A1 (fr) | 1992-08-13 | 1994-02-18 | Innotherapie Lab Sa | Anticorps monoclonaux anti-IL6R, et leurs applications. |
WO1995009873A1 (en) | 1993-10-06 | 1995-04-13 | Board Of Regents, The University Of Texas System | A monoclonal anti-human il-6 receptor antibody |
JPH07324097A (ja) | 1994-05-30 | 1995-12-12 | Daicel Chem Ind Ltd | インターロイキン6拮抗剤、及びペプチド類または医薬として許容されるその塩類 |
WO1996017869A2 (en) | 1994-12-06 | 1996-06-13 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Interleukin-6 (il-6) antagonists |
WO1996018648A1 (en) | 1994-12-14 | 1996-06-20 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Superagonists and antagonists of h il-6, and 3d modelling method for their selection |
JPH08245414A (ja) | 1995-01-27 | 1996-09-24 | Private Biolog Corp | Il−6関連疾患の治療用組成物および方法 |
US5571513A (en) | 1995-05-31 | 1996-11-05 | The Board Of Regents Of The University Of Oklahoma | Anti-gp130 monoclonal antibodies |
JPH08291199A (ja) | 1995-04-21 | 1996-11-05 | Diaclone Sa A Directoire & Conseil De Surveillance | 抗gp130モノクローナル抗体及びその使用 |
JPH08311098A (ja) | 1995-05-22 | 1996-11-26 | Daicel Chem Ind Ltd | 新規ペプチド類およびそれを含有するインターロイキン6拮抗剤 |
WO2001042484A1 (en) | 1999-12-09 | 2001-06-14 | Human Genome Sciences, Inc. | Il-6 like polynucleotide |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5670373A (en) | 1988-01-22 | 1997-09-23 | Kishimoto; Tadamitsu | Antibody to human interleukin-6 receptor |
DE122009000023I2 (de) * | 1989-07-20 | 2010-12-16 | Kishimoto | Antikörper gegen menschlichen Interleukin-6-Rezeptor |
US5888510A (en) | 1993-07-21 | 1999-03-30 | Chugai Seiyaku Kabushiki Kaisha | Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component |
WO1996012503A1 (fr) | 1994-10-21 | 1996-05-02 | Chugai Seiyaku Kabushiki Kaisha | Remede contre des maladies provoquees par la production d'il-6 |
AU6038196A (en) * | 1995-06-07 | 1996-12-30 | Private Biologicals Corporation | Compositions and methods of treating il-6 associated disease s |
US20020187150A1 (en) | 1997-08-15 | 2002-12-12 | Chugai Seiyaku Kabushiki Kaisha | Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient |
EP1074268B1 (en) * | 1998-03-17 | 2008-01-16 | Chugai Seiyaku Kabushiki Kaisha | Preventives or remedies for inflammatory intestinal diseases containing il-6 receptor antagonist antibodies |
KR100824824B1 (ko) | 2000-10-25 | 2008-04-23 | 추가이 세이야쿠 가부시키가이샤 | 아이엘-6 안타고니스트를 유효 성분으로서 함유하는건선의 예방 또는 치료제 |
JP4889187B2 (ja) | 2000-10-27 | 2012-03-07 | 中外製薬株式会社 | Il−6アンタゴニストを有効成分として含有する血中mmp−3濃度低下剤 |
UA80091C2 (en) | 2001-04-02 | 2007-08-27 | Chugai Pharmaceutical Co Ltd | Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist |
US20050090453A1 (en) * | 2003-01-15 | 2005-04-28 | Solbec Pharmaceuticals Co., Ltd. | Methods of modulating IL-6 |
AU2004204261A1 (en) * | 2003-01-15 | 2004-07-29 | Solbec Pharmaceuticals Limited | Method of modulating IL-6 |
EP1594897A4 (en) * | 2003-02-04 | 2006-11-08 | Centocor Inc | USE OF IL-6 ANTAGONISTS IN COMBINATION WITH STEROIDS FOR INCREASED APOPTOSIS |
GB2401040A (en) | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
US20060094645A1 (en) * | 2004-10-06 | 2006-05-04 | Oliver Lawless | Method for defining and treating chemically-induced immune disorders using tumor necrosis factor (TFNalpha), interleukin-1 (lL-1), and interleulin-6R(lL-6R) antagonists |
-
2004
- 2004-10-15 BR BRPI0415505-0A patent/BRPI0415505A/pt not_active IP Right Cessation
- 2004-10-15 MY MYPI20044273A patent/MY149856A/en unknown
- 2004-10-15 SI SI200431946T patent/SI1690550T1/sl unknown
- 2004-10-15 PL PL04792816T patent/PL1690550T3/pl unknown
- 2004-10-15 KR KR1020067007246A patent/KR101193708B1/ko not_active IP Right Cessation
- 2004-10-15 RU RU2006116896/15A patent/RU2392967C2/ru not_active IP Right Cessation
- 2004-10-15 CN CN200480031888XA patent/CN1874790B/zh not_active Expired - Fee Related
- 2004-10-15 ES ES04792816T patent/ES2392824T3/es active Active
- 2004-10-15 US US10/575,455 patent/US20070134242A1/en not_active Abandoned
- 2004-10-15 RU RU2010102911/15A patent/RU2554942C2/ru not_active IP Right Cessation
- 2004-10-15 NZ NZ546557A patent/NZ546557A/en not_active IP Right Cessation
- 2004-10-15 TW TW093131346A patent/TWI350175B/zh not_active IP Right Cessation
- 2004-10-15 DK DK04792816.3T patent/DK1690550T3/da active
- 2004-10-15 CA CA2542691A patent/CA2542691C/en not_active Expired - Fee Related
- 2004-10-15 AU AU2004281139A patent/AU2004281139B2/en not_active Ceased
- 2004-10-15 JP JP2005514876A patent/JP4651541B2/ja active Active
- 2004-10-15 AR ARP040103743A patent/AR046290A1/es unknown
- 2004-10-15 EP EP04792816A patent/EP1690550B1/en active Active
- 2004-10-15 WO PCT/JP2004/015674 patent/WO2005037315A1/ja active Application Filing
- 2004-10-15 MX MXPA06003768A patent/MXPA06003768A/es active IP Right Grant
-
2006
- 2006-04-10 IL IL174909A patent/IL174909A/en not_active IP Right Cessation
- 2006-04-12 ZA ZA200602973A patent/ZA200602973B/en unknown
- 2006-04-28 NO NO20061906A patent/NO20061906L/no not_active Application Discontinuation
-
2007
- 2007-02-09 HK HK07101545.1A patent/HK1096588A1/xx not_active IP Right Cessation
-
2008
- 2008-04-10 US US12/081,126 patent/US8802092B2/en active Active
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US521628A (en) | 1894-06-19 | Housekeeping-cabinet | ||
JPH02188600A (ja) | 1989-01-17 | 1990-07-24 | Chugai Pharmaceut Co Ltd | Bsf↓2アンタゴニスト |
JPH03219894A (ja) | 1990-01-26 | 1991-09-27 | Chuzo Kishimoto | gp130蛋白質に対する抗体 |
US5210075A (en) | 1990-02-16 | 1993-05-11 | Tanabe Seiyaku Co., Ltd. | Interleukin 6 antagonist peptides |
WO1992019759A1 (en) | 1991-04-25 | 1992-11-12 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin 6 receptor |
FR2694767A1 (fr) | 1992-08-13 | 1994-02-18 | Innotherapie Lab Sa | Anticorps monoclonaux anti-IL6R, et leurs applications. |
WO1995009873A1 (en) | 1993-10-06 | 1995-04-13 | Board Of Regents, The University Of Texas System | A monoclonal anti-human il-6 receptor antibody |
JPH07324097A (ja) | 1994-05-30 | 1995-12-12 | Daicel Chem Ind Ltd | インターロイキン6拮抗剤、及びペプチド類または医薬として許容されるその塩類 |
WO1996017869A2 (en) | 1994-12-06 | 1996-06-13 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Interleukin-6 (il-6) antagonists |
WO1996018648A1 (en) | 1994-12-14 | 1996-06-20 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Superagonists and antagonists of h il-6, and 3d modelling method for their selection |
JPH08245414A (ja) | 1995-01-27 | 1996-09-24 | Private Biolog Corp | Il−6関連疾患の治療用組成物および方法 |
JPH08291199A (ja) | 1995-04-21 | 1996-11-05 | Diaclone Sa A Directoire & Conseil De Surveillance | 抗gp130モノクローナル抗体及びその使用 |
JPH08311098A (ja) | 1995-05-22 | 1996-11-26 | Daicel Chem Ind Ltd | 新規ペプチド類およびそれを含有するインターロイキン6拮抗剤 |
US5571513A (en) | 1995-05-31 | 1996-11-05 | The Board Of Regents Of The University Of Oklahoma | Anti-gp130 monoclonal antibodies |
WO2001042484A1 (en) | 1999-12-09 | 2001-06-14 | Human Genome Sciences, Inc. | Il-6 like polynucleotide |
Non-Patent Citations (20)
Title |
---|
BIELEFELDT-OHMANN H. ET AL: "Interleukin-6 involvement in mesothelioma pathobiology: inhibition by interferon alpha alpha immunotherapy", 40, 1995, pages 241 - 250, XP002983492 * |
BIELEFELDT-OHMANN, CANCER IMMUNOL. IMMUNOTHER., vol. 40, 1995, pages 241 - 250 |
BRAKENHOFF ET AL., J. BIOL. CHEM., vol. 269, 1994, pages 86 - 93 |
HIGASHIHARA M.D. ET AL: "Increased Secretion of Interleukin-6 in Malignant Mesothelioma Cells from a Patient with Marked Thrombocytosis", CANCER, vol. 70, no. 8, 1992, pages 2105 - 2108, XP002983494 * |
HIGASHIHARA, CANCER, vol. 70, no. 8, 15 October 1992 (1992-10-15), pages 2105 - 2108 |
HIRATA, Y. ET AL., J. IMMUNOL., vol. 143, 1989, pages 2900 - 2906 |
HUANG, Y.W. ET AL., HYBRIDOMA, vol. 12, 1993, pages 621 - 630 |
MIHARA ET AL., IMMUNOLOGY LETTERS, vol. 84, 2002, pages 223 - 229 |
MONTI ET AL., CANCER RESEARCH, vol. 54, no. 16, 1994, pages 4419 - 4423 |
NAKA ET AL., ARTHRITIS RES, vol. 4, no. 3, 2002, pages S233 - S242 |
NAKANO T. ET AL: "Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma", BRITSH JOURNAL OF CANCER, vol. 77, no. 6, 1998, pages 907 - 912, XP002983493 * |
NAKANO, RESPIRATION, vol. 18, no. 9, 1999, pages 916 - 925 |
NAKANO: "Respiratory Diseases", JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2003, pages 570 - 573 |
NOVICK, D. ET AL., HYBRIDOMA, vol. 10, 1991, pages 137 - 146 |
SAVINO ET AL., EMBO J., vol. 13, 1994, pages 1357 - 1367 |
SUZUKI ET AL., EUR. J. IMMUNOL., vol. 22, 1992, pages 1989 - 1993 |
SUZUKI H. ET AL: "Anti-human interleukin-6 receptor antibody inhibits human myeloma growth in vivo", EUR.J.IMMUNOL., vol. 22, 1992, pages 1989 - 1993, XP001021610 * |
TADA: "Respiratory Diseases", JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 1999, pages 406 - 408 |
TAKAGI: "Respiratory Diseases", JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 1999, pages 469 - 472 |
VRIEND ET AL., J. MOL. GRAPHICS, vol. 8, 1990, pages 52 - 56 |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8470316B2 (en) | 2005-10-14 | 2013-06-25 | Chugai Seiyaku Kabushiki Kaisha | Agents for suppressing damage to transplanted islets after islet transplantation |
JP5191235B2 (ja) * | 2005-10-21 | 2013-05-08 | 中外製薬株式会社 | 心疾患治療剤 |
US8945558B2 (en) | 2005-10-21 | 2015-02-03 | Chugai Seiyaku Kabushiki Kaisha | Methods for treating myocardial infarction comprising administering an IL-6 inhibitor |
US11046784B2 (en) | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
US9260516B2 (en) | 2006-04-07 | 2016-02-16 | Osaka University | Method for promoting muscle regeneration by administering an antibody to the IL-6 receptor |
US9725514B2 (en) | 2007-01-23 | 2017-08-08 | Shinshu University | Chronic rejection inhibitor |
US11248053B2 (en) | 2007-09-26 | 2022-02-15 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
US11332533B2 (en) | 2007-09-26 | 2022-05-17 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant region |
US11371039B2 (en) | 2008-04-11 | 2022-06-28 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
US11359194B2 (en) | 2008-04-11 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding two or more antigen molecules repeatedly |
US10717781B2 (en) | 2008-06-05 | 2020-07-21 | National Cancer Center | Neuroinvasion inhibitor |
US10662245B2 (en) | 2008-09-26 | 2020-05-26 | Chugai Seiyaku Kabushiki Kaisha | Methods of reducing IL-6 activity for disease treatment |
WO2011013786A1 (ja) * | 2009-07-31 | 2011-02-03 | Maeda Shin | 癌の転移抑制剤 |
JP5752038B2 (ja) * | 2009-07-31 | 2015-07-22 | 愼 前田 | 癌の転移抑制剤 |
AU2010278067B2 (en) * | 2009-07-31 | 2016-10-27 | Shin Maeda | Cancer metastasis inhibitor |
JP6051049B2 (ja) * | 2010-05-28 | 2016-12-21 | 中外製薬株式会社 | 抗腫瘍t細胞応答増強剤 |
US9539322B2 (en) | 2010-05-28 | 2017-01-10 | National University Corporation Hokkaido University | Method of enhancing an antitumor T cell response by administering an anti-IL-6 receptor antibody |
US11891434B2 (en) | 2010-11-30 | 2024-02-06 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
US9951136B2 (en) | 2011-03-03 | 2018-04-24 | Apexigen, Inc. | Anti-IL-6 receptor antibodies and methods of use |
JP2014509510A (ja) * | 2011-03-03 | 2014-04-21 | アペクシジェン, インコーポレイテッド | 抗il−6受容体抗体およびその使用方法 |
US10782290B2 (en) | 2013-06-11 | 2020-09-22 | National Center Of Neurology And Psychiatry | Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy |
US10774148B2 (en) | 2015-02-27 | 2020-09-15 | Chugai Seiyaku Kabushiki Kaisha | Composition for treating IL-6-related diseases |
US10697883B2 (en) | 2015-05-19 | 2020-06-30 | National Center Of Neurology And Psychiatry | Method for determining application of therapy to multiple sclerosis (MS) patient |
US11851486B2 (en) | 2017-05-02 | 2023-12-26 | National Center Of Neurology And Psychiatry | Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils |
US11692037B2 (en) | 2017-10-20 | 2023-07-04 | Hyogo College Of Medicine | Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005037315A1 (ja) | 中皮腫治療剤 | |
US8173126B2 (en) | Blood VEGF level-lowering agent containing IL-6 antagonist as the active ingredient | |
US8597644B2 (en) | Method for treating psoriasis by administering an antibody to interleukin-6 receptor | |
CA2341239C (en) | A preventive or therapeutic agent for pancreatitis comprising il-6 antagonist as an active ingredient | |
JP4785534B2 (ja) | 血管炎治療剤 | |
US7955598B2 (en) | Therapeutic agent for chronic arthritides diseases of childhood-related diseases | |
WO2002036165A1 (fr) | Agent à base d'antagoniste d'il-6, faisant baisser le niveau des mmp-3 dans le sang | |
WO1998042377A1 (en) | Preventives or remedies for sensitized t cell-related diseases containing il-6 antagonists as the active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480031888.X Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005514876 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2006/003768 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 174909 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004281139 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006/02973 Country of ref document: ZA Ref document number: 2002/DELNP/2006 Country of ref document: IN Ref document number: 546557 Country of ref document: NZ Ref document number: 200602973 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2542691 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067007246 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12006500772 Country of ref document: PH |
|
ENP | Entry into the national phase |
Ref document number: 2004281139 Country of ref document: AU Date of ref document: 20041015 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004281139 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004792816 Country of ref document: EP Ref document number: 06044336 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006116896 Country of ref document: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007134242 Country of ref document: US Ref document number: 10575455 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2004792816 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0415505 Country of ref document: BR |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067007246 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 10575455 Country of ref document: US |